Company intelligence / Profile preview

Exosome Sciences

Hillsborough, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

Exosome Sciences is advancing the TauSome biomarker for use as a blood-based diagnostic test for chronic traumatic encephalopathy (CTE) in living individuals, targeting neurodegenerative and neurotrauma-related disease monitoring[1][6][7].

Therapeutic areas: Neurology
Modalities: Exosome-based biomarker
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Exosome Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exosome Sciences.

Explore the full profile